Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Parkinson’s Disease Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025

Table of Content

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis

Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       6.3.1. Levodopa Combination
       6.3.2. Dopamine Agonists
       6.3.3. MAO-B Inhibitors
       6.3.4. COMT Inhibitors
       6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       7.2.1. Oral
       7.2.2. Transdermal
       7.2.3. Subcutaneous
       7.2.4. Intestinal Infusion
       7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends

Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       8.3.1. Hospital Pharmacy
       8.3.2. Retail Pharmacy
       8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
       9.3.1. North America
       9.3.2. Europe
       9.3.3. Asia Pacific
       9.3.4. Latin America
       9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
       10.2.1. U.S.
       10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       10.3.1. Levodopa Combination
       10.3.2. Dopamine Agonists
       10.3.3. MAO-B Inhibitors
       10.3.4. COMT Inhibitors
       10.3.5. Others
10.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       10.4.1. Oral
       10.4.2. Transdermal
       10.4.3. Subcutaneous
       10.4.4. Intestinal Infusion
       10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       10.5.1. Hospital Pharmacy
       10.5.2. Retail Pharmacy
       10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
       10.6.1. By Country
       10.6.2. By Drug Class
       10.6.3. By Route of Administration
       10.6.4. By Distribution Channel

Chapter 11 Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       11.2.1. Germany
       11.2.2. U.K.
       11.2.3. France
       11.2.4. Italy
       11.2.5. Spain
       11.2.6. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       11.3.1. Levodopa Combination
       11.3.2. Dopamine Agonists
       11.3.3. MAO-B Inhibitors
       11.3.4. COMT Inhibitors
       11.3.5. Others
11.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       11.4.1. Oral
       11.4.2. Transdermal
       11.4.3. Subcutaneous
       11.4.4. Intestinal Infusion
       11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
       11.5.1. Hospital Pharmacy
       11.5.2. Retail Pharmacy
       11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
       11.6.1. By Country
       11.6.2. By Drug Class
       11.6.3. By Route of Administration
       11.6.4. By Distribution Channel

Chapter 12 Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       12.3.1. China
       12.3.2. India
       12.3.3. Japan
       12.3.4. Australia & New Zealand
       12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       12.4.1. Levodopa Combination
       12.4.2. Dopamine Agonists
       12.4.3. MAO-B Inhibitors
       12.4.4. COMT Inhibitors
       12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       12.5.1. Oral
       12.5.2. Transdermal
       12.5.3. Subcutaneous
       12.5.4. Intestinal Infusion
       12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       12.6.1. Hospital Pharmacy
       12.6.2. Retail Pharmacy
       12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
       12.7.1. By Country
       12.7.2. By Drug Class
       12.7.3. By Route of Administration
       12.7.4. By Distribution Channel

Chapter 13 Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       13.3.1. Brazil
       13.3.2. Mexico
       13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       13.4.1. Levodopa Combination
       13.4.2. Dopamine Agonists
       13.4.3. MAO-B Inhibitors
       13.4.4. COMT Inhibitors
       13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       13.5.1. Oral
       13.5.2. Transdermal
       13.5.3. Subcutaneous
       13.5.4. Intestinal Infusion
       13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
       13.6.1. Hospital Pharmacy
       13.6.2. Retail Pharmacy
       13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
       13.7.1. By Country/Sub-region
       13.7.2. By Drug Class
       13.7.3. By Route of Administration
       13.7.4. By Distribution Channel

Chapter 14 Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
       14.3.1. GCC Countries
       14.3.2. South Africa
       14.3.3. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
       14.4.1. Levodopa Combination
       14.4.2. Dopamine Agonists
       14.4.3. MAO-B Inhibitors
       14.4.4. COMT Inhibitors
       14.4.5. Others
14.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
       14.5.1. Oral
       14.5.2. Transdermal
       14.5.3. Subcutaneous
       14.5.4. Intestinal Infusion
       14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
       14.6.1. Hospital Pharmacy
       14.6.2. Retail Pharmacy
       14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
       14.7.1. By Country/Sub-region
       14.7.2. By Drug Class
       14.7.3. By Route of Administration
       14.7.4. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Parkinson’s Disease Therapeutics Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
       15.3.1. AbbVie, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       15.3.2. UCB Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       15.3.3. Merck & Co., Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.4. Valeant Pharmaceuticals International, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.5. Novartis AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.6. Boehringer Ingelheim GmbH.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.7. GlaxoSmithKline plc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.8. Teva Pharmaceutical Industries Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.9. STADA Arzneimittel AG.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.10. Impax Laboratories, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

       15.3.11. F. Hoffmann-La Roche Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote